Many patients with end-stage heart disease die because of the scarcity of donor hearts. A
total artificial heart (TAH), an implantable machine that replaces the heart, has so far been …

The aim of this review is to describe the current use, indications, and outcomes of the
Syncardia temporary total artificial heart (TAH)(Syncardia Systems, Tucson, AZ, USA), the …

There is an urgent need for ventricular assist devices (VADs) that can assist in complex
biological functions such as the contraction of heart muscle. Although the design …

Introduction Organ shortage, subsequent use of extended donor criteria organs and high-
risk recipients needing redo-surgery are increasing the complexity of heart transplantation …

Introduction: Since the first total artificial heart (TAH) surgery in a human patient performed in
1969, over 1300 devices have been implanted worldwide. Patients are benefiting from …

Introduction End-stage heart failure (HF) is a condition whose only successful long-term
treatment, with a survival of more than 10 years, is heart transplantation. However, limited …

Minimizing of the life-threatening thrombo-emboli formation in pulsatile heart assist devices
by a new biomimetic heart valve design is presently one of the most important problems in …

Introducción La insuficiencia cardiaca (IC) terminal es una afección cuyo único tratamiento
exitoso a largo plazo, con una supervivencia de más de 10 años, es el trasplante cardíaco …

The SynCardia temporary total artificial heart (TAH-t) is a pneumatically driven pulsatile
device that replaces a patient's ventricles and all four valves. It is now available in two sizes …

The effect of type of mechanical circulatory support on stroke risk during the early post-
transplant period remains undefined in patients bridged to transplant. This study assesses if …